In vivo preservation of steroid specificity in CWR22 xenografts having a mutated androgen receptor

Prostate. 2003 Sep 15;57(1):1-7. doi: 10.1002/pros.10266.


Background: In vitro studies of CWR22 tumor cells lack steroid specificity. We sought to determine if CWR22 xenografts also lack steroid specificity.

Methods: We injected castrated nude mice with CWR22 tumor cells (6 x 10(6) cells) and implanted Alzet osmotic pumps that delivered approximately 1 mg steroid/kg body weight/day.

Results: Serum PSA levels were detectable in intact mice and castrated mice treated with testosterone (T), but not in those treated with estradiol (E(2)), progesterone (P), or flutamide (F). T maintained mean tumor weight similar to that in intact mice (P = NS). We observed no tumors in castrated mice or mice treated with E(2), P, or F, and tumor histology was consistent with weights.

Conclusions: The mutation of the androgen receptor (H874Y) that occurs in the CWR22 xenograft model of human prostate cancer does not significantly affect in vivo steroid specificity for E(2), P, or F.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Androgen Antagonists / pharmacology
  • Animals
  • Estradiol / pharmacology*
  • Flutamide / pharmacology
  • Gonadal Steroid Hormones / pharmacology*
  • Male
  • Mice
  • Mice, Nude
  • Muscle, Skeletal / anatomy & histology
  • Neoplasm Transplantation
  • Orchiectomy
  • Organ Size
  • Progesterone / pharmacology*
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / physiopathology*
  • Receptors, Androgen / genetics*
  • Seminal Vesicles / anatomy & histology
  • Testosterone / pharmacology*
  • Transplantation, Heterologous


  • Androgen Antagonists
  • Gonadal Steroid Hormones
  • Receptors, Androgen
  • Testosterone
  • Progesterone
  • Estradiol
  • Flutamide
  • Prostate-Specific Antigen